Core--Drug development

核心--药物开发

• 批准号: 6660912
• 负责人: DAVID J WATERS
• 金额: $ 21.7万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6660912
• 关键词: antineoplastics; biomedical facility; cell line; cytotoxicity; drug design /synthesis /production; drug screening /evaluation; neoplasm /cancer; oncology; tissue /cell culture

The Drug Development Shared Resource provides essential services for Purdue Cancer Center investigators whose research focuses on the design, synthesis and evaluation of novel anticancer agents. The need for a highly integrated in vitro and in vivo drug evaluation service for candidate drugs mandated the creation of this Shared Resource from two previously separate facilities (Cytotoxicity and Athymic Mouse). The Drug Development Shared Resource will provide investigators with the in vitro assays, in vivo xenograft models, pharmacokinetics expertise, and pathology support needed to conduct a rational evaluation of new drugs. Human tumor cell lines of many histologic types will be available for use; a standard panel will be available for drug candidates where the mechanism of action is unknown, but mechanistic information will be used to select cell lines for specific targeted drug candidates. The majority of these cell lines will also be available as xenografts so that promising candidates in vitro can be carried forward directly into in vivo models. Most drug evaluations in vivo will rely on standard subcutaneous xenograft models; unique metastatic xenograft models are also available in the Shared Resource. Facility staff will work with investigators to select appropriate in vitro and in vivo models, drug vehicle, and administration schedule. Expertise in pharmacokinetics and experimental pathology is available to assist in study design and evaluation of tumor response. Ultimately, the goal of the Drug Development Shared Resource is to provide the essential expertise, services and data needed to move promising drug candidates toward further preclinical development in preparation for clinical evaluation.

药物开发共享资源为普渡大学癌症中心研究人员提供基本服务，他们的研究重点是新型抗癌药物的设计、合成和评估。候选药物对高度集成的体外和体内药物评价服务的需求要求从两个以前独立的设施（细胞毒性和无胸腺小鼠）创建此共享资源。药物开发共享资源将为研究人员提供对新药进行合理评价所需的体外测定、体内异种移植模型、药代动力学专业知识和病理学支持。许多组织学类型的人类肿瘤细胞系将可供使用；将为作用机制未知的候选药物提供标准组，但将使用机制信息为特定目标候选药物选择细胞系。这些细胞系中的大多数也将作为异种移植物提供，以便体外有前途的候选细胞可以直接转移到体内模型中。大多数体内药物评估将依赖于标准皮下异种移植模型；共享资源中还提供了独特的转移异种移植模型。设施工作人员将与研究人员合作，选择适当的体外和体内模型、药物载体和给药时间表。药代动力学和实验病理学方面的专业知识可协助研究设计和肿瘤反应评估。最终，药物开发共享资源的目标是提供必要的专业知识、服务和数据，以推动有前途的候选药物进一步进行临床前开发，为临床评估做好准备。